Stock listing
Neurotech International Ltd.
Selected listing: NTI · ASX · AUD · AU
Neurotech International Ltd. (ASX:NTI), Health Technology. Latest release Sep 20, 2026: NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study.
- Ticker
- ASX:NTI
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Medical Specialties
- Exchange
- ASX
- Currency
- AUD
About Neurotech International Ltd.
The company focuses on developing innovative neurotechnology solutions. Its mission is to improve the quality of life for individuals with neurological conditions.
Latest news from Neurotech International Ltd.
NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study
September 20, 2026
Receipt of Binding Commitments for $4.5m Placement
August 3, 2026
Neurotech secures $3.15 million R&D tax incentive loan
July 14, 2026
US FDA clears IND for NTI164
July 13, 2026
NTI secures Notices of Allowance for US patent applications
July 1, 2026
Research Neurotech International Ltd.
Neurotech International Ltd. company profile
View the public company page for Neurotech International Ltd. on 6ix.
Neurotech International Ltd. news
Read company news and market updates connected to Neurotech International Ltd..
Neurotech International Ltd. investor events
Find investor webinars, events, and replay context for Neurotech International Ltd..